[go: up one dir, main page]

IS5264A - Ný þíeno[2,3-d]pýrimidíndíón, blöndur sem innihalda þau, aðferðir til framleiðslu þeirra og notkun þeirra í lækningalyf - Google Patents

Ný þíeno[2,3-d]pýrimidíndíón, blöndur sem innihalda þau, aðferðir til framleiðslu þeirra og notkun þeirra í lækningalyf

Info

Publication number
IS5264A
IS5264A IS5264A IS5264A IS5264A IS 5264 A IS5264 A IS 5264A IS 5264 A IS5264 A IS 5264A IS 5264 A IS5264 A IS 5264A IS 5264 A IS5264 A IS 5264A
Authority
IS
Iceland
Prior art keywords
methods
pyrimidin
dione
medicaments
preparation
Prior art date
Application number
IS5264A
Other languages
English (en)
Other versions
IS1983B (is
Inventor
Cheshire David
Cooke Andrew
Cooper Martin
Donald David
Furber Mark
Perry Matthew
Thorne Philip
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS5264A publication Critical patent/IS5264A/is
Publication of IS1983B publication Critical patent/IS1983B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)
IS5264A 1997-05-28 1999-11-23 Ný þíeno[2,3-d]pýrimidíndíón, blöndur sem innihalda þau, aðferðir til framleiðslu þeirra og notkun þeirra í lækningalyf IS1983B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702001A SE9702001D0 (sv) 1997-05-28 1997-05-28 Novel compounds
PCT/SE1998/000935 WO1998054190A1 (en) 1997-05-28 1998-05-18 Novel compounds

Publications (2)

Publication Number Publication Date
IS5264A true IS5264A (is) 1999-11-23
IS1983B IS1983B (is) 2005-01-14

Family

ID=20407123

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5264A IS1983B (is) 1997-05-28 1999-11-23 Ný þíeno[2,3-d]pýrimidíndíón, blöndur sem innihalda þau, aðferðir til framleiðslu þeirra og notkun þeirra í lækningalyf

Country Status (28)

Country Link
US (2) US6180635B1 (is)
EP (1) EP0991653B1 (is)
JP (1) JP2002500666A (is)
KR (1) KR100561988B1 (is)
CN (1) CN1122037C (is)
AT (1) ATE226205T1 (is)
AU (1) AU723708B2 (is)
BR (1) BR9809481A (is)
CA (1) CA2289509C (is)
CZ (1) CZ297536B6 (is)
DE (1) DE69808765T2 (is)
DK (1) DK0991653T3 (is)
EE (1) EE04018B1 (is)
ES (1) ES2184270T3 (is)
HU (1) HU226627B1 (is)
ID (1) ID28432A (is)
IL (2) IL132763A0 (is)
IS (1) IS1983B (is)
NO (1) NO323752B1 (is)
NZ (1) NZ500853A (is)
PL (1) PL199567B1 (is)
PT (1) PT991653E (is)
RU (1) RU2225410C2 (is)
SE (1) SE9702001D0 (is)
SK (1) SK283589B6 (is)
TR (1) TR199902904T2 (is)
UA (1) UA61111C2 (is)
WO (1) WO1998054190A1 (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB2361917A (en) * 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
WO2001083489A1 (en) * 2000-05-04 2001-11-08 Astrazeneca Ab THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
GB2363377B (en) * 2000-06-14 2004-06-09 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
EP1370562A1 (en) * 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
WO2003055482A1 (en) * 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
PL215132B1 (pl) * 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300117D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel Compounds
RU2332420C2 (ru) * 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
EP1904438B1 (en) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
CN101263131B (zh) 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
BRPI0617436B8 (pt) * 2005-10-19 2021-05-25 Kissei Pharmaceutical derivado heterocíclico fundido, composição farmacêutica compreendendo o mesmo e usos do dito derivado na prevenção ou tratamento de doença dependente de hormônio sexual e na regulação da reprodução, contracepção ou indução de ovulação
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
CA2670788A1 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
EP2008656A1 (en) * 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
CA2756535A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
PL2776038T3 (pl) 2011-11-11 2018-06-29 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
CN105793267B (zh) 2013-10-07 2018-02-06 拜耳制药股份公司 环状噻吩并尿嘧啶甲酰胺类及其用途
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
KR20180082556A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 피라졸 acc 억제제 및 그의 용도
EP3380479B1 (en) 2015-11-25 2022-12-07 Gilead Apollo, LLC Triazole acc inhibitors and uses thereof
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
MX2018010427A (es) 2016-03-02 2019-03-06 Gilead Apollo Llc Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
JP2019529452A (ja) 2016-09-23 2019-10-17 バイエル・アクチエンゲゼルシヤフト Ｎ３−環状置換チエノウラシルおよびその使用
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002432A1 (fr) * 1987-09-16 1989-03-23 Taiho Pharmaceutical Company, Limited Derives de thienopyrimidine
TW276256B (is) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
EE04018B1 (et) 2003-04-15
NO995810D0 (no) 1999-11-26
CZ297536B6 (cs) 2007-01-03
EE9900539A (et) 2000-06-15
IL132763A (en) 2007-03-08
IS1983B (is) 2005-01-14
HUP0003355A3 (en) 2003-03-28
ID28432A (id) 2001-05-24
HUP0003355A2 (hu) 2001-02-28
CN1264382A (zh) 2000-08-23
SK151399A3 (en) 2000-05-16
AU723708B2 (en) 2000-09-07
PT991653E (pt) 2003-02-28
CN1122037C (zh) 2003-09-24
UA61111C2 (uk) 2003-11-17
JP2002500666A (ja) 2002-01-08
NO323752B1 (no) 2007-07-02
CZ420199A3 (cs) 2000-07-12
BR9809481A (pt) 2000-06-20
KR100561988B1 (ko) 2006-03-17
CA2289509A1 (en) 1998-12-03
CA2289509C (en) 2007-10-02
TR199902904T2 (xx) 2000-06-21
EP0991653B1 (en) 2002-10-16
IL132763A0 (en) 2001-03-19
RU2225410C2 (ru) 2004-03-10
SE9702001D0 (sv) 1997-05-28
ES2184270T3 (es) 2003-04-01
ATE226205T1 (de) 2002-11-15
AU7680898A (en) 1998-12-30
US6342502B1 (en) 2002-01-29
NZ500853A (en) 2001-05-25
SK283589B6 (sk) 2003-10-07
EP0991653A1 (en) 2000-04-12
NO995810L (no) 2000-01-27
WO1998054190A1 (en) 1998-12-03
DE69808765D1 (de) 2002-11-21
US6180635B1 (en) 2001-01-30
HU226627B1 (en) 2009-05-28
PL199567B1 (pl) 2008-10-31
KR20010013107A (ko) 2001-02-26
DE69808765T2 (de) 2003-07-24
DK0991653T3 (da) 2003-01-06
PL337126A1 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
IS5264A (is) Ný þíeno[2,3-d]pýrimidíndíón, blöndur sem innihalda þau, aðferðir til framleiðslu þeirra og notkun þeirra í lækningalyf
ATE223413T1 (de) Neuartige verbindungen
PL336230A1 (en) Novel chemical compounds
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
PT1416935E (pt) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
HK1046527A1 (zh) 金剛烷衍生物
PL377239A1 (pl) Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych
ZA9811796B (en) New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them.
EP0821587A4 (en) COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
HUP0401292A3 (en) Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
IS5082A (is) Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja
NZ335938A (en) Prodrug forms and new analogues of camptothecin, their use as medicaments
HUP0003219A3 (en) Phthalazine derivatives, process for producing them and pharmaceutical compositions containing them and use of the compounds for producing pharmaceutical compositions useful for treating erectile dysfunction
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
ATE272642T1 (de) Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel
MXPA03003198A (es) 3,4-dihidro-pirido [1,2-a]pirimidinas sustituidas.
AU2000267375A1 (en) Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
EP0182277A3 (en) Pyrazine diazohydroxide compounds and methods for their production and use
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS